Treatment of Alzheimer’s Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
Author/Authors: Teodoro del Ser, Klaus C. Steinwachs, Hermann J. Gertz, María V. Andrés, Belén Gómez-Carrillo, Miguel Medina, Joan A. Vericat, Pilar Redondo, David Fleet and Teresa León
Evidence for the irreversible inhibition of Glycogen Synthase Kinase-3beta by tideglusib
Author/Authors: J.M. Domínguez, A. Fuertes, L. Orozco, M. del Monte-Millán, E. Delgado, M. MedinaRecent Developments in Tau-based Therapeutics for Neurodegenerative Diseases
Author/Authors: M. MedinaDeconstructing GSK-3: The Fine Regulation of Its Activity
Author/Authors: M. Medina, F. WandosellModulation of GSK-3 as a therapeutic strategy on taupathologies
Author/Authors: M. Medina, J.J. Garrido, F. WandosellOvercoming Cell Death and Tau Phosphorylation Mediated by PI3KInhibition: A Cell Assay to Measure Neuroprotection
Author/Authors: D. Simon, M. Medina, J. Avila and F. WandosellGlycogen Synthase Kinase-3 (GSK-3) Inhibitors For The Treatment of Alzheimer’s Disease
Author/Authors: M. Medina, J. ÁvilaTau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits
Author/Authors: Elena Gómez de Barreda, Mar Pérez, Pilar Gómez Ramos, Javier de Cristobal, Patricia Martín-Maestro, Asunción Morán, Hana N. Dawson, Michael P. Vitek, José J. Lucas, Félix Hernández, Jesús AvilaPhase IIa Clinical Trial on Alzheimer's disease with NP12, a GSK-3 inhibitor
Author/Authors: T. del SerNeuronal in vitro models for the estimation of acute systemic toxicity
Author/Authors: A. Forsby, A.K. Bal-Price, A. Camins, S. Coecke, N. Fabre, H. Gustafsson, P. Honegger, A. Kinsner-Ovaskainen, M. Pallas, V. Rimbau, E. Rodríguez-Farré, C. Suñol, J.A. Vericat, M.G. Zurich